Literature DB >> 16464404

Correlative studies in neuro-oncology trials: should they influence treatment?

Monika E Hegi1, Roger Stupp.   

Abstract

Recent molecular correlative studies accompanying clinical trials in glioma have provided strong evidence for prognostic markers and predictive factors for treatment response. However, to what extent can these markers influence the limited choice of therapeutic options? Do we further validate the markers in the next trials or move on, incorporate the markers for patient selection or stratification, aim at improving the modestly effective treatments by adding new drugs, and develop alternative therapy strategies for patients selected for their bad predictor?

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16464404     DOI： 10.1007/s11912-006-0010-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  36 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Authors:  Ranjit K Goudar; Qing Shi; Mark D Hjelmeland; Stephen T Keir; Roger E McLendon; Carol J Wikstrand; Elizabeth D Reese; Charles A Conrad; Peter Traxler; Heidi A Lane; David A Reardon; Webster K Cavenee; Xiao-Fan Wang; Darell D Bigner; Henry S Friedman; Jeremy N Rich
Journal:  Mol Cancer Ther       Date:  2005-01       Impact factor: 6.261

3.  The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

Authors:  Iwan Beuvink; Anne Boulay; Stefano Fumagalli; Frederic Zilbermann; Stephan Ruetz; Terence O'Reilly; Francois Natt; Jonathan Hall; Heidi A Lane; George Thomas
Journal:  Cell       Date:  2005-03-25       Impact factor: 41.582

4.  Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma.

Authors:  Anjan Misra; Malgorzata Pellarin; Janice Nigro; Ivan Smirnov; Dan Moore; Kathleen R Lamborn; Daniel Pinkel; Donna G Albertson; Burt G Feuerstein
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

5.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

6.  Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.

Authors:  Jean-Blaise Wasserfallen; Sandrine Ostermann; Alessia Pica; René-Olivier Mirimanoff; Serge Leyvraz; Jean-Guy Villemure; Roger Stupp
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

7.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

8.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Authors:  H S Friedman; R E McLendon; T Kerby; M Dugan; S H Bigner; A J Henry; D M Ashley; J Krischer; S Lovell; K Rasheed; F Marchev; A J Seman; I Cokgor; J Rich; E Stewart; O M Colvin; J M Provenzale; D D Bigner; M M Haglund; A H Friedman; P L Modrich
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

9.  Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

Authors:  K A Jaeckle; H J Eyre; J J Townsend; S Schulman; H M Knudson; M Belanich; D B Yarosh; S I Bearman; D J Giroux; S C Schold
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

Authors:  M Belanich; M Pastor; T Randall; D Guerra; J Kibitel; L Alas; B Li; M Citron; P Wasserman; A White; H Eyre; K Jaeckle; S Schulman; D Rector; M Prados; S Coons; W Shapiro; D Yarosh
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.